ArticleBMC cancer2022

Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.

Cuiying He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.